167 related articles for article (PubMed ID: 15325801)
21. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
Miki S; Ksander B; Streilein JW
Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
[TBL] [Abstract][Full Text] [Related]
22. Deficient tumor-specific immunity in old mice: in vivo mediation by suppressor cells, and correction of the defect by interleukin 2 supplementation in vitro but not in vivo.
Bruley-Rosset M; Payelle B
Eur J Immunol; 1987 Mar; 17(3):307-12. PubMed ID: 2952510
[TBL] [Abstract][Full Text] [Related]
23. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
24. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
25. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
26. CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection.
Wirth S; van den Broek M; Frossard CP; Hügin AW; Leblond I; Pircher H; Hauser C
Cell Immunol; 2000 May; 202(1):13-22. PubMed ID: 10873302
[TBL] [Abstract][Full Text] [Related]
27. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
28. CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis.
Tsagozis P; Karagouni E; Dotsika E
Parasite Immunol; 2003; 25(11-12):569-79. PubMed ID: 15053778
[TBL] [Abstract][Full Text] [Related]
29. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
31. Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum.
Xu Y; Zhu KJ; Zhu N; Jiang DH; Chen XZ; Cheng H
Clin Exp Dermatol; 2009 Mar; 34(2):229-35. PubMed ID: 19077104
[TBL] [Abstract][Full Text] [Related]
32. The role of L3T4-positive T lymphocytes in the generation of anti-tumor immunity in the mouse.
Yamamoto H; Takata M; Fujimoto S
Jpn J Cancer Res; 1987 Feb; 78(2):176-84. PubMed ID: 2951356
[TBL] [Abstract][Full Text] [Related]
33. Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells.
Huster KM; Koffler M; Stemberger C; Schiemann M; Wagner H; Busch DH
Eur J Immunol; 2006 Jun; 36(6):1453-64. PubMed ID: 16637009
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
35. Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry.
Ito N; Nakamura H; Tanaka Y; Ohgi S
Cancer; 1999 Jun; 85(11):2359-67. PubMed ID: 10357406
[TBL] [Abstract][Full Text] [Related]
36. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
37. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
38. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
[TBL] [Abstract][Full Text] [Related]
39. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
40. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
